1. Home
  2. ARQT vs PDFS Comparison

ARQT vs PDFS Comparison

Compare ARQT & PDFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARQT
  • PDFS
  • Stock Information
  • Founded
  • ARQT 2016
  • PDFS 1992
  • Country
  • ARQT United States
  • PDFS United States
  • Employees
  • ARQT N/A
  • PDFS N/A
  • Industry
  • ARQT Biotechnology: Pharmaceutical Preparations
  • PDFS EDP Services
  • Sector
  • ARQT Health Care
  • PDFS Technology
  • Exchange
  • ARQT Nasdaq
  • PDFS Nasdaq
  • Market Cap
  • ARQT 1.1B
  • PDFS 1.1B
  • IPO Year
  • ARQT 2020
  • PDFS N/A
  • Fundamental
  • Price
  • ARQT $13.92
  • PDFS $27.20
  • Analyst Decision
  • ARQT Strong Buy
  • PDFS Strong Buy
  • Analyst Count
  • ARQT 5
  • PDFS 3
  • Target Price
  • ARQT $17.00
  • PDFS $42.33
  • AVG Volume (30 Days)
  • ARQT 2.2M
  • PDFS 158.0K
  • Earning Date
  • ARQT 02-25-2025
  • PDFS 02-13-2025
  • Dividend Yield
  • ARQT N/A
  • PDFS N/A
  • EPS Growth
  • ARQT N/A
  • PDFS 56.69
  • EPS
  • ARQT N/A
  • PDFS 0.11
  • Revenue
  • ARQT $138,708,000.00
  • PDFS $170,505,000.00
  • Revenue This Year
  • ARQT $209.03
  • PDFS $10.26
  • Revenue Next Year
  • ARQT $49.00
  • PDFS $20.06
  • P/E Ratio
  • ARQT N/A
  • PDFS $246.82
  • Revenue Growth
  • ARQT 182.84
  • PDFS 3.19
  • 52 Week Low
  • ARQT $3.11
  • PDFS $26.60
  • 52 Week High
  • ARQT $16.20
  • PDFS $39.70
  • Technical
  • Relative Strength Index (RSI)
  • ARQT 51.79
  • PDFS 39.23
  • Support Level
  • ARQT $13.10
  • PDFS $26.60
  • Resistance Level
  • ARQT $16.20
  • PDFS $29.50
  • Average True Range (ATR)
  • ARQT 0.95
  • PDFS 0.81
  • MACD
  • ARQT -0.26
  • PDFS -0.06
  • Stochastic Oscillator
  • ARQT 26.45
  • PDFS 20.69

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About PDFS PDF Solutions Inc.

PDF Solutions Inc offers products and services designed to empower engineers and data scientists across the semiconductor ecosystem to improve the yield, quality, and profitability of their products. The solutions combine proprietary software, physical intellectual property (or IP) for integrated circuit (or IC) designs, electrical measurement hardware tools, various methodologies, and professional services. The company's products and services are sold to integrated device manufacturers (or IDMs), fabless semiconductor companies, foundries, outsourced semiconductor assembly and test (or OSATs), and system houses.

Share on Social Networks: